Abstract:UNLABELLEDIn this study, we examined the factors that may influence tumor dosimetry in the radioimmunotherapy of solid, CEA-expressing cancers.METHODSData from 119 tumors in 93 patients with CEA-expressing cancers were analyzed. The patients underwent radioimmunotherapy with the 131I-labeled IgG1 anti-CEA antibodies NP-4 (Ka = 10(8) M-1) or MN-14 (Ka = 10(9) M-1), its humanized form hMN-14, as well as the anticolon-specific antigen-p (CSAp) antibody, Mu-9. For dosimetry, the biodistribution, targeting kinetics and cumulated activity of tumors and organs were determined from planar and SPECT imaging.RESULTSAn inverse logarithmic relationship between tumor size and antibody uptake was found for both anti-CEA antibodies, whereas no such relationship was found for Mu-9. The absolute tumor uptake was identified as the most important factor determining the radiation dose to the tumor (r = 0.9), with the biological half-life of the antibody in the tumor being of secondary importance (r = 0.5). No significant difference in tumor uptake was found between both anti-CEA antibodies, despite their tenfold difference in affinity. At comparable masses, colorectal and medullary thyroid cancers had significantly higher tumor uptakes (p = 0.02), as well as tumor-to-red marrow dose ratios, than other cancer types. The tumor half-lives of the anti-CEA antibodies were significantly lower in colorectal than in all other tumor types (p = 0.01).CONCLUSIONIn radioimmunotherapy, tumor uptake appears to be the most important dose-determining factor. Differences in antibody affinity are reflected by differences in the biological half-life, not the absolute uptake. Especially favorable conditions for anti-CEA antibodies seem to prevail in colorectal cancer patients having minimal disease, as well as in medullary thyroid cancer, where cytotoxic tumor doses might be expected. Antimucin antibodies may have a particular advantage in the treatment of patients with larger colorectal tumors.

Structural Analysis of Anti-cancer Antibody, CLN-IgG, and Anti-Idiotypic Antibody, Idio-No. 3, for the Study of Idiotope Image Transmission: An Insight into Antigen-Specific Human Monoclonal Antibody Therapy

Characterization and Evaluation of A Novel Anti-Muc-1 Monoclonal Antibody: Induction of the Idiotypic Network in Experimental Mice

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

Anti‐idiotypic antibodies: biological function and structural studies

Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy

Anti-idiotype antibodies to the 9.1C3 blocking antibody used to probe the lethal hit stage of NK cell-mediated cytolysis.

Identification of CD73 as the Antigen of an Antigen-Unknown Monoclonal Antibody Established by Exosome Immunization, and Its Antibody–Drug Conjugate Exerts an Antitumor Effect on Glioblastoma Cell Lines

Multiple-tumor binding specificity and high tumor uptake of monoclonal antibody 3H11

Molecular Cloning of a Tumor-Associated Antigen Recognized by Monoclonal Antibody 3H11

A monoclonal antiidiotypic antibody with rheumatoid factor activity defines a cross-reactive idiotope on murine anticollagen antibodies.

Screening Non-neutralizing Anti-idiotype Antibodies Against a Drug Candidate for Total Pharmacokinetic and Target Engagement Assay

An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication

Radioiodination, Purification, and Evaluation of Antihuman Tumor-Derived Immunoglobulin G Light Chain Monoclonal Antibody in Tumor-Bearing Nude Mice.

Variables Influencing Tumor Dosimetry in Radioimmunotherapy of CEA-expressing Cancers with Anti-Cea and Antimucin Monoclonal Antibodies.

Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders

Purification and Immunochemical Studies of the Protein-Bound J Substance from Cattle Serum

Cloning of the Cdna Fragment of a Tumor Associated Antigen Recognized by Monoclonal Antibody 3H11

Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy

[The Study of Immunotherapy of Ovarian Carcinoma with Anti-Idiotypic Antibody].

[Construction, Expression and Activity of a Single Chain Antibody to Gastric Cancer Cells].

Antitumor Effects of Nonconjugated Murine Lym-2 and Human-Mouse Chimeric Cll-1 Monoclonal Antibodies Against Various Human Lymphoma Cell Lines in Vitro and in Vivo